139022-27-8

Usage

Uses

Used in Medicinal Chemistry:
Imidazo[1,2-a]pyridine, 6-fluoro(9CI) is used as a building block or intermediate in the synthesis of pharmaceutical drugs. Its unique structure allows for the development of new drug candidates with potential therapeutic properties.
Used in Agriculture:
In the agricultural industry, Imidazo[1,2-a]pyridine, 6-fluoro(9CI) may be utilized as a component in the development of agrochemicals, such as pesticides or herbicides, due to its chemical properties.
Used in Materials Science:
Imidazo[1,2-a]pyridine, 6-fluoro(9CI) could be employed in the field of materials science for the design and synthesis of new materials with specific properties, such as electronic, optical, or mechanical characteristics.
Used as a Research Tool in Chemical Biology:
Imidazo[1,2-a]pyridine, 6-fluoro(9CI) may also serve as a valuable research tool in chemical biology, where it can be used to study biological processes or to develop new probes for investigating molecular interactions.

Upstream product

• 21717-96-4 2-amino-5-fluoropyridine 
• 17157-48-1 bromoacetaldehyde 
• 107-20-0 2-chloroethanal 

Downstream Products

• 1219127-01-1 6-fluoro-3-iodoimidazo[1,2-a]pyridine 
• 1235993-30-2 6-fluoro-3-nitro-imidazo[1,2-a]pyridine 
• 1338248-71-7 6-fluoro-3-phenylimidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases

Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.

Heteroaryl imidazolone derivatives as jak inhibitors

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Imidazopyridine derivatives as JAK inhibitors

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

New adenosine receptor ligands and uses thereof

The present invention provides new compounds with high affinity for adenosine A2A receptors. It also provides antagonists of adenosine A2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and di

IMIDAZO[1,2-α ]PYRIDINYL BISPHOSPHONATES

Novel imidazo[1,2-α]pyridinyl bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.